DISCLOSURE POLICY
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as an “ineligible company”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf of all other authors/contributors, if applicable.
Ineligible company: Any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition. |
Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. |
Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship. |
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
For course-specific disclosure listings, please refer to the disclosure insert provided at your course site.
ADMR Planning Committee:
Susan Miller Briggs, MD, MPH, FACS
No relevant financial relationship(s) with ineligible companies to disclose
David V. Shatz, MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
David. P. Blake, MD, MPH, DMCC, FACS, FACHE, FSIS
No relevant financial relationship(s) with ineligible companies to disclose
ADMR Subject Medical Experts:
Christopher T. Born MD, FACS, FAAOS, FIOTA
BioIntraface, Stockholder, Board of Directors, Chief Medical Officer
BI Medical, Stockholder, Chief Medical Officer
IlluminOss, Consultant Fees, Chief Medical Officer
Stryker Orthopaedics, Royalties, Product Designer
Mark W. Bowyer MD, FACS, FRCS (Glasg) FRCS-hon (Thailand), DMCC
No relevant financial relationship(s) with ineligible companies to disclose
Eric H. Bradburn, DO, MS, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Marko Bukur, MD, FACS
Zimmer Biomet, Consulting Fees, Educator/Consultant
Eileen Bulger, MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Jeannette Capella, MD, MEd, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Jay Doucet MD, MSc, FRCSC, FACS, RDMS
No relevant financial relationship(s) with ineligible companies to disclose
Alexander L. Eastman, MD, MPH, FACS, FAEMS
No relevant financial relationship(s) with ineligible companies to disclose
Mary E. Fallat MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Adam D. Fox DO, FACS
Teleflex, Consulting Fees, Medical Advisory Board
Annekathryn Goodman, MD, MPH, MA, MS, FACS, FACOG
No relevant financial relationship(s) with ineligible companies to disclose
Sharon Henry MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
John B. Holcomb MD, FACS
Aspem Medical, Salary, Consultant
CCJ Medical, Equity, Board member
Decisio Health, Equity, Board member
Hemostatics, Equity, Board member
QinFlow, Equity, Board member
WFIRM, Salary, Consultant
Zibrio, Equity, Board member
Donald H. Jenkins MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
David F. Lawlor MD, FACS, FRCSC
Zim Vie, Honoraria, Lecturer
Highridge Medical, Honoraria, Lecturer
Manuel Lorenzo MD, MBA, FACS, FCCM
No relevant financial relationship(s) with ineligible companies to disclose
Tina L. Palmieri MD, FACS, FABA, MCCM
No relevant financial relationship(s) with ineligible companies to disclose
Gerd Daniel Pust, MD, MBA, FACS, FCCM, DABS
No relevant financial relationship(s) with ineligible companies to disclose
A. Tyler Putnam, II, MD, FACS, FCCM
No relevant financial relationship(s) with ineligible companies to disclose
Kyle N. Remick, MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Peter Rhee MD, MPH, FACS, FCCM, DMCC
No relevant financial relationship(s) with ineligible companies to disclose
Martin A. Schreiber MD, FACS, FCCM
CSL Behring, Institutional Support, Advisory Panel Member
Haemonetics, Institutional Support, Advisory Panel Member
John T. Schulz III, MD, PhD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Robert L. Sheridan, MD, FACS
No relevant financial relationship(s) with ineligible companies to disclose
Jeffrey S. Upperman, MD, FACS, FAAP
No relevant financial relationship(s) with ineligible companies to disclose
ADMR Consultants:
Edward (Ted) M. Kennedy, EdD
No relevant financial relationship(s) with ineligible companies to disclose
Julie Cwik, MSEd, MSLIS
No relevant financial relationship(s) with ineligible companies to disclose
